HIV Preventive Vaccines (original) (raw)

• Merson MH. Slowing the spread of HIV: agenda for the 1990s. Science 1993; 260: 1266–8.
  PubMed CAS Google Scholar
• Mertens TE, Burton A, Stoneburner R, et al. Global estimates and epidemiology of HIV infections and AIDS. AIDS 1994; 8 Suppl. 1: S361–72.
  Google Scholar
• Esparza J, Qsmanov S, Kallings LO. Planning for HIV vaccine trials: the World Health Organization perspective. AIDS 1991; 5 Suppl. 2: S159–63.
  PubMed Google Scholar
• Esparza J, Osmanov S. The development and evaluation of HIV vaccines. Curr Opin Infect Dis 1993: 6: 218–29
  Google Scholar
• Walker MC, Fast PE. Clinical trials of experimental AIDS vaccines. AIDS 1994; 8 Suppl. 1: S213–36.
  Google Scholar
• Haynes BE Scientific and social issues of human immunodeficiency virus vaccine development. Science 1993; 260: 1279–86
  PubMed CAS Google Scholar
• Hilleman MR. Vaccinology, immunology, and comparative pathogenesis of measles in the quest for a preventative against AIDS. AIDS Res Hum Retroviruses 1994; 10: 3–12.
  PubMed CAS Google Scholar
• Hoth DF, Bolognesi DP, Corey L, et al. HIV vaccine development: a progress report (NIH Conference). Ann Int Med 1994; 8: 603–11.
  Google Scholar
• Letvin N. Vaccines against human immunodeficiency virus — progress and prospects. N Engl J Med 1993; 329: 1400–5.
  PubMed CAS Google Scholar
• Norley SG, Vogel T, Kurth R. Anti-HIV vaccines: current status and future development. Drugs 1993; 46: 947–60.
  PubMed CAS Google Scholar
• Paul WE. Reexamining AIDS research priorities. Science 1994; 267: 633–6.
  Google Scholar
• Vermund SH, Schultz AM, Hoff R. Prevention of HIV/AIDS with vaccines. Curr Opin Infect Dis 1994; 7: 82–94.
  Google Scholar
• Clerici M. Cell-mediated immunity in HIV infection. AIDS 1993; 7 Suppl. 1: S135–40.
  PubMed Google Scholar
• Cohen J. AIDS research shifts to immunity. Science 1992; 257: 152–3.
  PubMed CAS Google Scholar
• Mosmann TR. Cytokine patterns during the progression to AIDS. Science 1994; 265: 193–4.
  PubMed CAS Google Scholar
• Pantaleo G, Graziosi C, Fauci AS. The immunopathogenesis of human immunodeficiency virus infection. N Engl J Med 1993; 328: 327–35.
  PubMed CAS Google Scholar
• Fauci AS. Multifactorial nature of human immunodeficiency virus disease: implications for therapy. Science 1993; 262: 1011–8.
  PubMed CAS Google Scholar
• Levy JA. HIV pathogenesis and long term survival. AIDS 1993; 7: 1401–10.
  PubMed CAS Google Scholar
• Rowe P. Resistance to HIV infection. Lancet 1993; 341: 624.
  PubMed CAS Google Scholar
• Clerici MJ, Giorgi JV, Chuo C-C, et al. Cell-mediated immune response to human immunodeficiency virus (HIV) type 1 in seronegative homosexual men with recent sexual exposure to HIV-1. J Infect Dis 1992; 165: 1012–9.
  PubMed CAS Google Scholar
• Clerici MJ, Levine HA, Kessler A, et al. HIV-specific T-helper activity in seronegative health care workers exposed to contaminated blood. JAMA 1994; 217: 42–6.
  Google Scholar
• De Maria A, Cirillo C, Moretta L. Occurrence of human immunodeficiency virus type 1 (HIV-1)-specific cytolytic T cell activity in apparently uninfected children born to HIV-1 infected mothers. J Infect Dis 1994; 170: 1296–9.
  PubMed Google Scholar
• Kiprow DD, Sheppard HW, Hanson CV. Alloimmunization to prevent AIDS? Science 1994; 263: 737–8
  Google Scholar
• Rowland-Jones SL, Nixon DF, Aldhous MC, et al. HIV-specific cytotoxic T-cell activity in an HIV-exppsed but uninfected infant. Lancet 1993; 341: 860–1.
  PubMed CAS Google Scholar
• Shearer GM, Clerici M, Dalgleish A. Alloimmunization as an AIDS vaccine? Science 1993; 262: 161–2
  PubMed CAS Google Scholar
• Willeford DM, Bwayo JJ, Hensel M, et al. Human immunodeficiency virus infection among high-risk seronegative prostitutes in Nairobi. J Infect Dis 1993; 167: 1414–7.
  Google Scholar
• Niu MT, Stein DS, Schnittman SM. Primary human immunodeficiency virus type 1 infection: review of pathogenesis and early treatment intervention in human and animal retrovirus infections. J Infect Dis 1993; 168: 1490–501.
  PubMed CAS Google Scholar
• Koup RA, Ho DD. Shutting down HIV. Nature 1994; 370: 416.
  PubMed CAS Google Scholar
• Koup RA, Safrit JT, Cao Y, et al. Temporal association of cellular immune responses with the initial control of viremia in primary human immunodeficiency virus type 1 syndrome. J Virol 1994; 68: 4650–5.
  PubMed CAS Google Scholar
• Pantaleo G, Demarest JF, Soudeyns H, et al. Major expansion of CD8+ T cells with a predominant Vβ usage during the primary immune response to HIV. Nature 1994; 370: 463–7.
  PubMed CAS Google Scholar
• Moore J, Cao Y, Ho DD, et al. Development of the anti-gp120 antibody response during seroconversion to human immunodeficiency virus type 1. J Virol 1994; 68: 5142–55.
  PubMed CAS Google Scholar
• Baltimore D. Lessons from people with nonprogressive HIV infection. N Engl J Med 1995; 332: 259–60.
  PubMed CAS Google Scholar
• Pantaleo G, Menzo S, Vaccarezza M, et al. Studies in subjects with long-term nonprogressive human immunodeficiency virus infection. N Engl J Med 1995; 332: 209–16.
  PubMed CAS Google Scholar
• Mellors JW, Kingsley LA, Rinaldo CR, et al. Quantitation of HIV-1 RNA in plasma predicts outcome after seroconversion. Ann Int Med 1995; 122: 573–9.
  PubMed CAS Google Scholar
• Chakrabarti L, Cumont M-C, Montagnier L, et al. Variable course of primary simian immunodeficiency virus infection in lymph nodes: relation to disease progression. J Virol 1994; 68: 6634–42.
  PubMed CAS Google Scholar
• Hirsch VM, Goldstein S, Hynes NA, et al. Prolonged clinical latency and survival of macaques given a whole inactivated simian immunodeficiency virus vaccine. J Infect Dis 1994; 170: 51–9.
  PubMed CAS Google Scholar
• Cohen J. A new goal: preventing disease, not infection. Science 1993; 262: 1820–1.
  PubMed CAS Google Scholar
• Miedema F, Meyaard L, Klein MR. Protection from HIV infection or AIDS? Science 1993; 262: 1074–5
  PubMed CAS Google Scholar
• Salk J, Bretscher PA, Salk PL, et al. A strategy for prophylactic vaccines against HIV Science 1993; 260: 1270–2
  PubMed CAS Google Scholar
• Embretson J, Zupancic M, Ribas JL, et al. Massive covert infection of helper T lymphocytes and macrophages by HIV during the incubation period of AIDS. Nature 1993; 362: 359–62.
  PubMed CAS Google Scholar
• Pantaleo G, Graziosi C, Demarest JF, et al. HIV infection is active and progressive in lymphoid tissue during the clinically latent stage of disease. Nature 1993; 362: 355–8.
  PubMed CAS Google Scholar
• Ho DD, Neumann AU, Perelson AS, et al. Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection. Nature 1995; 373: 123–6.
  PubMed CAS Google Scholar
• Wei X, Ghosh SK, Taylor ME, et al. Viral dynamics in human immunodeficiency virus type 1 infection. Nature 1995; 373: 117–22.
  PubMed CAS Google Scholar
• Veugelers PJ, Page KA, Tindall B, et al. Determinants of HIV disease progression among homosexual men registered in the tricontinental seroconverter study. Am J Epidemiol 1994; 140: 747–58.
  PubMed CAS Google Scholar
• Easterbrook PJ. Non-progression in HIV infection. AIDS 1994; 8: 1179–82.
  PubMed CAS Google Scholar
• Buchbinder SP, Katz MH, Hessol NA, et al. Long-term HIV-1 infection without immunological progression. AIDS 1994; 8: 1123–8.
  PubMed CAS Google Scholar
• Cao Y, Quin L, Zhang L, et al. Virologic and immunologic characterization of long-term survivors of human immunodeficiency virus type 1 infection. N Engl J Med 1995; 332: 201–8.
  PubMed CAS Google Scholar
• Wong MT, Warren RQ, Anderson SA, et al. Longitudinal analysis of the humoral response to human immunodeficiency virus type 1 (HIV-1) gp160 epitopes in rapidly progressing and nonprogressing HIV-1-infected subjects. J Infect Dis 1993; 168: 1523–7.
  PubMed CAS Google Scholar
• Huang Y, Zhang L, Ho DD. Characterization of nef sequences in long-term survivors of human immunodeficiency virus type 1 infection. J Virol 1995; 69: 93–100.
  PubMed CAS Google Scholar
• Kirchhoff F, Greenough TC, Brettler DB, et al. Absence of intact nef sequences in a long-term survivor with nonprogressive HIV-1 infection. N Engl J Med 1995; 332: 228–32.
  PubMed CAS Google Scholar
• Conley AJ, Kessler JA, Boots LJ, et al. Neutralization of divergent human immunodeficiency virus type 1 variants and primary isolates by IAM-41-2F5, an anti-gp41 human monoclonal antibody. Proc Natl Acad Sci USA 1994; 91: 3348–52.
  PubMed CAS Google Scholar
• Earl PL, Broder CC, Long D, et al. Native oligomeric human immunodeficiency virus type 1 envelope glycoprotein elicits diverse monoclonal antibody reactivities. J Virol 1994; 68: 3015–26.
  PubMed CAS Google Scholar
• Kang C-Y, Hariharan K, Nara PL, et al. Immunization with a soluble CD4-gp120 complex preferentially induces neutralizing anti-human immunodeficiency virus type 1 antibodies directed to conformation-dependent epitopes of gp120. J Virol 1994; 68: 5854–62.
  PubMed CAS Google Scholar
• Laal S, Burda S, Gorny MK, et al. Synergistic neutralization of human immunodeficiency virus type 1 by combinations of human monoclonal antibodies. J Virol 1994; 68: 4001–8.
  PubMed CAS Google Scholar
• Moore JP, Ho DD. Antibodies to discontinuous or conformationally sensitive epitopes on the gp120 glycoprotein of human immunodeficiency virus type 1 are highly prevalent in sera of infected humans. J Virol 1993; 67: 863–75.
  PubMed CAS Google Scholar
• Muster T, Steindl F, Purtscher M, et al. A conserved neutralizing epitope on gp41 human immunodeficiency virus type 1. J Virol 1993; 67: 6642–7.
  PubMed CAS Google Scholar
• Myers G, Korber BTM, Smith RF, et al. Human retroviruses and AIDS. Los Alamos: Theoretical Biology and Biophysics Group, Los Alamos National Laboratory, 1993.
  Google Scholar
• WHO Network for HIV Isolation and Characterization. HIV-type 1 variation in World Health Organization-sponsored vaccine evaluation sites: genetic screening, sequence analysis, and preliminary biological characterization of selected viral strains. AIDS Res Human Retroviruses 1994; 10: 1327–43.
  Google Scholar
• Bachmann ME, Delwart EL, Shpaer EG, et al. Rapid genetic characterization of HIV strains from four World Health Organization-sponsored vaccine evaluation sites using a heteroduplex mobility assay. AIDS Res Hum Retroviruses 1994; 10: 1345–53.
  PubMed CAS Google Scholar
• Bobkov A, Cheingsong-Popov R, Garaev M, et al. Identification of an env G subtype and heterogeneity of HIV-1 strains in the Russian Federation and Belarus. AIDS 1994; 8: 1649–55.
  PubMed CAS Google Scholar
• Cernescu CE, Tardei G, Necula A, et al. The serologic significance of F viral genotype for human immunodeficiency virus type 1 epidemic. J Infect Dis 1994; 170: 1043–4.
  PubMed CAS Google Scholar
• Dumitrescu O, Kalish ML, Kliks SC, et al. Characterization of human immunodeficiency virus type 1 isolates from children in Rumania: identification of a hew envelope subtype. J Infect Dis 1994; 169: 281–8.
  PubMed CAS Google Scholar
• Gao F, Yue L, Craig S, et al. Genetic variation of HIV type 1 in four World Health Organization-sponsored vaccine evaluation sites: generation of functional envelope (glycoprotein 160) clones representative of sequence subtypes A, B, C, and E. AIDS Res Hum Retroviruses 1994; 10: 1359–68.
  PubMed CAS Google Scholar
• Janssens W, Heydrickx L, Van de Peer Y, et al. Molecular phylogeny of part of the env gene of HIV-1 strains isolated in Côte d’Ivoire. AIDS 1994; 8: 21–6.
  PubMed CAS Google Scholar
• Korber BTM, Osmanov S, Esparza J, et al. The World Health Organization Global Programme on AIDS proposal for standardization of HIV sequence nomenclature. AIDS Res Hum Retroviruses 1994; 10: 1355–8.
  PubMed CAS Google Scholar
• Louwagie J, McCutchan F, Peeters M, et al. Phylogenetic analysis of gag genes from seventy international HIV-1 isolates provided evidence for multiple genotypes. AIDS 1993; 7: 769–80.
  PubMed CAS Google Scholar
• Louwagie J, Delwart EL, Mullins JI, et al. Genetic analysis of HIV-1 isolates from Brazil reveals the presence of two distinct genotypes. AIDS Res Hum Retroviruses 1994; 10: 561–7.
  PubMed CAS Google Scholar
• Louwagie J, Janssens W, Mascola J, et al. Genetic diversity of the envelope glycoprotein from human immunodeficiency virus type 1 isolates of African origin. J Virol 1995; 69: 263–71.
  PubMed CAS Google Scholar
• Sabino EC, Shpaer EG, Morgado MG, et al. Identification of human immunodeficiency virus type 1 envelope genes recombinant between subtypes B and F in two epidemiological linked individuals from Brazil. J Virol 1994; 68: 6340–6.
  PubMed CAS Google Scholar
• Sharp PM, Robertson DL, Gao F. Origins and diversity of human immunodeficiency viruses. AIDS 1994; 4 Suppl. 1: S27–42.
  Google Scholar
• Gurtler LG, Hauser PH, Eberle J, et al. A new subtype of human immunodeficiency virus type 1 (MVP-5180) from Cameroon. J Virol 1994; 68: 1581–5.
  PubMed CAS Google Scholar
• Nkengasong JN, Peeters M, Ndumbe P, et al. Cross-neutralizing antibodies to HIV-1ANT70and HIV-1IIIb in sera of African and Belgian HIV-1-infected individuals. AIDS 1994; 8: 1089–96.
  PubMed CAS Google Scholar
• Peeters M, Nkengasong J, Willems B, et al. Antibodies to V3 loop peptides derived from chimpanzee lentiviruses and the divergent HIV-1ANT-70 isolate in human sera from different geographic regions. AIDS 1994; 8: 1657–61.
  PubMed CAS Google Scholar
• Vanden Hasevelde M, Decourt J-L, De Leys RJ, et al. Genomic cloning and complete sequence analysis of a highly divergent African human immunodeficiency virus isolate. J Virol 1994; 68: 1586–96.
  Google Scholar
• Zekeng L, Gurtler L, Afane Ze E, et al. Prevalence of HIV-1 subtype O infection in Cameroon: preliminary findings. AIDS 1994; 8: 1626–7.
  PubMed CAS Google Scholar
• Cheingsong-Popov R, Lister S, Callow D, et al. Serotyping HIV type 1 by antibody binding to the V3 loop: relationship to viral genotype. AIDS Res Hum Retroviruses 1994; 10: 1379–86.
  PubMed CAS Google Scholar
• Pau C-P, Kai M, Holloman-Candal DL, et al. Antigenic variation and serotyping of HIV type 1 from four World Health Organization-sponsored HIV vaccine sites. AIDS Res Hum Retroviruses 1994; 10: 1369–77.
  PubMed CAS Google Scholar
• Osmanov S, Heyward WL, Esparza J. The World Health Organization network for HIV isolation and characterization. AIDS Res Hum Retroviruses 1994; 10: 1325–6.
  PubMed CAS Google Scholar
• Pau C-P, Kai M, Holloman-Candal DL, et al. Antigenic variation and serotyping of HIV type 1 from four World Health Organization-sponsored HIV vaccine sites. AIDS Res Hum Retroviruses 1994; 10: 1369–77.
  PubMed CAS Google Scholar
• Moore JP, McCutchan FE, Poon S-W, et al. Exploration of antigenic variation in gp120 from clades A through F of human immunodeficiency virus type 1 by using monoclonal antibodies. J Virol 1994; 68: 8350–64.
  PubMed CAS Google Scholar
• Mascola JR, Louwagie J, McCutchan FE, et al. Two antigenically distinct subtypes of human immunodeficiency virus type 1: viral genotype predicts neutralization serotype. J Infect Dis 1994; 169: 48–54.
  PubMed CAS Google Scholar
• De Wolf F, Hogervorst E, Goudsmit J, et al. Syncytium-inducing and non-syncytium inducing capacity of human immunodeficiency virus type 1 subtypes other than B: phenotypic and genotypic characteristics. AIDS Res Hum Retroviruses 1994; 10: 1387–400.
  PubMed Google Scholar
• Rubsamen-Waigmann H, Von Briesen H, Holmes H, et al. Standard conditions of virus isolation reveal biological variability of HIV type 1 in different regions of the world. AIDS Res Hum Retroviruses 1994; 10: 1401–8.
  PubMed CAS Google Scholar
• Zhu T, Mo H, Wang N, et al. Genotypic and phenotypic characterization of HIV-1 in patients with primary infection. Science 1993; 261: 1179–81.
  PubMed CAS Google Scholar
• Bou-Habib DC, Roderiquez G, Oravecz T, et al. Cryptic nature of envelope V3 region epitopes protects primary monocytotropic human immunodeficiency virus type 1 from antibody neutralization. J Virol 1994; 68: 6006–13.
  PubMed CAS Google Scholar
• Sawyer LSW, Terri Wrin M, Crawford-Miksza L, et al. Neutralization sensitivity of human immunodeficiency virus type 1 is determined in part by the cell in which the virus is propagated. J Virol 1994; 68: 1342–9.
  PubMed CAS Google Scholar
• Fultz PN. Nonhuman primate models for AIDS. Clin Infect Dis 1993; 17 Suppl. 1: S230–5.
  PubMed Google Scholar
• Warren JT, Dolatshahi M. Annual update survey of worldwide HIV, SIV, and SHIV challenge studies in vaccinated nonhuman primates. J Med Primatol 1994; 23: 184–225.
  PubMed CAS Google Scholar
• Stott EJ. Anti-cell antibody in macaques. Nature 1992; 353: 393.
  Google Scholar
• Arthur LO, Bess JW, Sowder RC, et al. Cellular proteins bound to immunodeficiency viruses: implications for pathogenesis and vaccines. Science 1992; 258: 1935–8.
  PubMed CAS Google Scholar
• Fultz PN, Nara P, Barre-Sinoussi F, et al. Vaccine protection of chimpanzees against challenge with HIV-1-infected peripheral blood mononuclear cells. Science 1992; 256: 1687–90.
  PubMed CAS Google Scholar
• Girard M, Meignier B, Matthews T, et al. Protection of chimpanzees against heterologous HIV-1 challenge. In: Girard M, Valette L, editors. Retroviruses of human AIDS and related animal diseases. 9e Colloque des ‘Cent Gardes’; 1994 Oct 24–26; Marnes-La-Coquette. Paris: Fondation Marcel Merieux, 1995: 263–6.
  Google Scholar
• Graham BS. Serological responses to candidate AIDS vaccines. AIDS Res Hum Retroviruses 1994; 10 Suppl. 10: S145–8.
  PubMed Google Scholar
• de Vries P, Heeney JL, Boes J, et al. Protection of rhesus macaques from SIV infection by immunization with different experimental SIV vaccines. Vaccine 1994; 12: 1443–52.
  PubMed Google Scholar
• Giavedoni LD, Planelles V, Haigwood NL, et al. Immune response of rhesus macaques to recombinant simian immunodeficiency virus gp130 does not protect from challenge infection. J Virol 1993; 67: 577–83.
  PubMed CAS Google Scholar
• Israel ZR, Edmonson PF, Maul DH, et al. Incomplete protection, but not suppression of virus burden, elicited by subunit simian immunodeficiency virus vaccines. J Virol 1994; 68: 1843–53.
  PubMed CAS Google Scholar
• Putkonen P, Bjprling E, Akerblom L, et al. Long-standing protection of macaques against cell-free HIV-2 with a HIV-2 iscom vaccine. J Acquir Immune Defic Syndr 1994; 7: 551–9.
  PubMed CAS Google Scholar
• Wang CY, Looney DJ, Li ML, et al. Long term high titer neutralizing activity induced by octameric synthetic HIV-1 antigen. Science 1991; 254: 285–8.
  PubMed CAS Google Scholar
• Griffiths JC, Harris SJ, Layton GT, et al. Hybrid human immunodeficiency virus gag particles as an antigen carrier system: induction of cytotoxic T-cell and humoral responses by a gag: V3 fusion. J Virol 1993; 67: 3191–8.
  PubMed CAS Google Scholar
• Martin SJ, Vyakarnam A, Cheingsong-Popov R, et al. Immunization of human HIV-seronegative volunteers with recombinant p17/p24: Ty virus-like particles elicits HIV-1 p24-specific cellular and humoral immune responses. AIDS 1993; 7: 1315–23.
  PubMed CAS Google Scholar
• Wagner R, Boltz T, Deml L, et al. Induction of cytolytic T lymphocytes directed towards the V3 loop of the human immunodeficiency virus type 1 external glycoprotein gp120 by p55gag/V3 chimeric vaccinia viruses. J Gen Virol 1993; 74: 1261–9.
  PubMed CAS Google Scholar
• Wolf HJ, Modrow S, Wagner R. The HIV-1 Pr55gag protein: understanding the mechanism of virus assembly as a basis for the development of novel therapeutics and vaccines. In: Girard M, Valette L, editors. Retroviruses of human AIDS and related animal diseases. 8e Colloque des ‘Cent Gardes’; 1993 Oct 25–27: Marnes-La-Coquette. Paris: Fondation Marcel Merieux, 1994: 299–307.
  Google Scholar
• Adams SE, Paoletti E. Use of new vectors for the development of vaccines. AIDS 1993; 7 Suppl. 1: S141–6.
  PubMed Google Scholar
• Andino R, Silvera D, Suggett SD, et al. Engineering poliovirus as a vaccine vector for the expression of diverse antigens. Science 1994; 265: 1448–51.
  PubMed CAS Google Scholar
• Natuk RJ, Lubeck MD, Chanda PK, et al. Immunogenicity of Adeno-HIV vaccines in chimpanzees. In: Girard M, Valette L, editors. Retroviruses of human AIDS and related animal diseases. 8e Colloque des ‘Cent Gardes’; 1993 Oct 25–27: Marnes-La-Coquette. Paris: Fondation Marcel Merieux, 1994: 115–20.
  Google Scholar
• Tartaglia J, Franchini G, Robert-Guroff M, et al. Highly attenuated poxvirus vector strains, NY VAC and ALVAC, in retrovirus vaccine development. In: Girard M, Valette L, editors. Retroviruses of human AIDS and related animal diseases. 8e Colloque des ‘Cent Gardes’; 1993 Oct 25–27: Marnes-La-Coquette. Paris: Fondation Marcel Merieux, 1994: 293–8.
  Google Scholar
• Vella C, Ferguson M, Dunn G, et al. Characterization and primary structure of a human immunodeficiency virus type 1 (HIV-1) neutralization domain as presented by a poliovirus type 1/HIV-1 chimera. J Gen Virol 1993; 74: 2601–7.
  Google Scholar
• Daniel MD, Kirchoff F, Czajak SC, et al. Protective effects of a live attenuated SIV vaccine with a deletion in the nef gene. Science 1992; 258: 1938–41.
  PubMed CAS Google Scholar
• Desrosiers RC. HIV with multiple gene deletions as a live attenuated vaccine for AIDS. AIDS Res Hum Retroviruses 1992; 8: 411–21.
  PubMed CAS Google Scholar
• Kirchoff F, Kestler HW, Desrosiers RC. Upstream U3 sequences in simian immunodeficiency virus are selectively deleted in vivo in the absence of an intact nef gene. J Virol 1994; 68: 2031–7.
  Google Scholar
• Ilyinskii PO, Daniel MD, Simon MA, et al. The role of upstream U3 sequences in the pathogenesis of simian immunodeficiency virus-induced AIDS in rhesus monkeys. J Virol 1994; 68: 5933–44.
  PubMed CAS Google Scholar
• Kieney MP, Aubertin AM, Benavente A, et al. Protection of monkeys against SIV infection with live attenuated viruses. In: Girard M, Valette L, editors. Retroviruses of human AIDS and related animal diseases. 8e Colloque des ‘Cent Gardes’; 1993 Oct 25–27: Marnes-La-Coquette. Paris: Fondation Marcel Merieux, 1994: 211–8.
  Google Scholar
• Desrosiers RC, Daniel MD, Wyand MS, et al. A radical strategy for development of a vaccine against HIV-1. In: Girard M, Valette L, editors. Retroviruses of human AIDS and related animal diseases. 8e Colloque des ‘Cent Gardes’; 1993 Oct 25–27: Marnes-La-Coquette. Paris: Fondation Marcel Merieux, 1994: 205–9.
  Google Scholar
• Norley S. Live attenuated immunodeficiency viruses: interesting scientific tools or vaccines of the future? In: Girard M, Valette L, editors. Retroviruses of human AIDS and related animal diseases. 8e Colloque des ‘Cent Gardes’; 1993 Oct 25–27: Marnes-La-Coquette. Paris: Fondation Marcel Merieux, 1994: 199–203
  Google Scholar
• Bolognesi DP. Controversies in science: a live-virus AIDS vaccine? Not yet, it is too early to consider use of a live-attenuated virus vaccine against HIV-1. J NIH Res 1994; 6: 55, 59–62
  Google Scholar
• Cohen J. At conference, hope for success is further attenuated. Science 1994; 266: 1154.
  PubMed CAS Google Scholar
• Desrosiers RC. Controversies in science: a live-virus AIDS vaccine? Yes, it is time to consider use of a live-attenuated virus vaccine against HIV-1. J NIH Res 1994; 6: 54, 56–59
  Google Scholar
• World Health Organization Working Group. Feasibility of developing live attenuated HIV vaccines: conclusions and recommendations. AIDS Res Hum Retroviruses 1994; 10: 221–2.
  Google Scholar
• Cichutek K. Nucleic acid immunization: a prophylactic gene therapy? Vaccine 1994; 12: 1520–5
  PubMed CAS Google Scholar
• Donnelly JJ, Ulmer JB, Liu MA. Immunization with polynucleotides: a novel approach to vaccination. Immunologist 1994; 2: 20–6.
  CAS Google Scholar
• Fynan EF, Webster RG, Fuller DH, et al. DNA vaccines: protective immunizations by parenteral, mucosal, and gene-gun inoculations. Proc Natl Acad Sci USA 1993; 90: 11478–82.
  PubMed CAS Google Scholar
• Raz E, Carson DA, Parker SE, et al. Intradermal gene immunization: the possible role of DNA uptake in the induction of cellular immunity to viruses. Proc Natl Acad Sci USA 1994; 91: 9519–23.
  PubMed CAS Google Scholar
• Robertson JS. Safety considerations for nucleic acid vaccines. Vaccine 1994; 12: 1526–8.
  PubMed CAS Google Scholar
• Robinson JL, Fynan EF, Webster RG, et al. Gene vaccines, a new approach to immunization. In: Girard M, Valette L, editors. Retroviruses of human AIDS and related animal diseases. 8e Colloque des ‘Cent Gardes’; 1993 Oct 25–27: Marnes-La-Coquette. Paris: Fondation Marcel Merieux, 1994: 335–41.
  Google Scholar
• Schoedel F, Aguado M-T, Lambert P-H. Introduction: nucleic acid vaccines, WHO, Geneva, 17–18 May 1994. Vaccine 1994; 12: 1491–2.
  Google Scholar
• Smith HA. Regulatory considerations for nucleic acid vaccines. Vaccine 1994; 12: 1515–9.
  PubMed CAS Google Scholar
• Wang B, Ugen KE, Srikantan V, et al. Gene inoculation generates immune responses against human immunodeficiency virus type 1. Proc Natl Acad Sci USA 1993; 90: 4156–60.
  PubMed CAS Google Scholar
• Fast PE, Walker MC, Ketter N, et al. Evaluation of candidate HIV-1 prophylactic vaccines in phase I/II trials. In: Girard M, Valette L, editors. Retroviruses of human AIDS and related animal diseases. 8e Colloque des ‘Cent Gardes’; 1993 Oct 25–27: Marnes-La-Coquette. Paris: Fondation Marcel Merieux, 1994: 271–9.
  Google Scholar
• Schwartz DH, Gorse G, Clements ML, et al. Induction of HIV-1-neutralising and syncytium-inhibiting antibodies in uninfected recipients of HIV-1IIB rgp120 subunit vaccine. Lancet 1993; 342: 69–73.
  PubMed CAS Google Scholar
• Berman PW, Eastman DJ, Wilkes DM, et al. Comparison of the immune response to recombinant gp120 in humans and chimpanzees. AIDS 1994; 8: 591–601.
  PubMed CAS Google Scholar
• Belshe RB, Graham MS, Keefer MC, et al. Neutralizing antibodies to HIV-1 in seronegative volunteers immunized with recombinant gp120 from the MN strain of HIV-1. JAMA 1994; 272: 475–80.
  PubMed CAS Google Scholar
• Kahn JO, Sinangil F, Baenziger J, et al. Clinical and immunological responses to human immunodeficiency virus (HIV) type 1SF2 gp120 subunit vaccine combined with MF59 adjuvant with or without muramyl tripeptide dipalmitoyl phosphatidylethanolamine in non-HIV-infected human volunteers. J Infect Dis 1994; 170: 1288–91.
  PubMed CAS Google Scholar
• Belshe RB, Clements ML, Dolin R, et al. Safety and immunogenicity of a fully glycosylated recombinant gp160 human immunodeficiency virus type 1 vaccine in subjects at low risk of infection. J Infect Dis 1993; 168: 1387–95.
  PubMed CAS Google Scholar
• Stanhope PE, Clements ML, Siliciano RE Human CD4+ cytolytic T lymphocyte responses to a human immunodeficiency virus type 1 gp160 subunit vaccine. J Infect Dis 1993; 168: 92–100
  PubMed CAS Google Scholar
• Excler JL, Salmon D, Pialoux G, et al. Combined antigen regimes for vaccination against HIV. In: Girard M, Valette L, editors. Retroviruses of human AIDS and related animal diseases. 8e Colloque des ‘Cent Gardes’; 1993 Oct 25–27: Marnes-La-Coquette. Paris: Fondation Marcel Merieux, 1994: 281–4.
  Google Scholar
• Bolognesi DP. Vaccine clinical trials: chairman’s overview. In: Girard M, Valette L, editors. Retroviruses of human AIDS and related animal diseases. 8e Colloque des ‘Cent Gardes’; 1993 Oct 25–27: Marnes-La-Coquette. Paris: Fondation Marcel Merieux, 1994: 267–70.
  Google Scholar
• El-Daher N, Keefer MC, Reichman RC, et al. Persisting human immunodeficiency virus type 1 gp160-specific human T lymphocyte responses including CD8+ cytotoxic activity after receipt of envelope vaccines. J Infect Dis 1993; 168: 306–13.
  PubMed CAS Google Scholar
• Graham BS, Gorse GJ, Schwartz DH, et al. Determinants of antibody response after recombinant gp160 boosting in vaccinia-naive volunteers primed with gp160-recombinant vaccinia virus. J Infect Dis 1994; 170: 782–6.
  PubMed CAS Google Scholar
• McElrath MJ, Corey L, Berger D, et al. Immune responses elicited by recombinant vaccinia-human immunodeficiency virus (HIV) envelope and HIV envelope protein: analysis of the durability of responses and effect of repeated boosting. J Infect Dis 1994; 169: 41–7.
  PubMed CAS Google Scholar
• O’Hagan DT, McGee JP, Wang CY, et al. The UBI multicomponent HIVR vaccine: the advantages of controlled release microparticles. In: Girard M, Valette L, editors. Retroviruses of human AIDS and related animal diseases. 8e Colloque des ‘Cent Gardes’; 1993 Oct 25–27: Marnes-La-Coquette. Paris: Fondation Marcel Merieux, 1994: 309–13.
  Google Scholar
• Belshe RB, Bolognesi DP, Clements ML, et al. HIV infection in vaccinated volunteers. JAMA 1994; 272: 431.
  PubMed CAS Google Scholar
• Cohen J. Will media reports KO upcoming real-life trials? Science 1994; 264: 1660
  PubMed CAS Google Scholar
• Mascola JR, McNeil JG, Burke DS. AIDS vaccines: are we ready for human efficacy trials? JAMA 1994; 272: 488–9
  PubMed CAS Google Scholar
• Lawrence DN, Esparza J, Zoon KC. Considerations for commencement of HIV vaccine efficacy trials: a working group summary. AIDS Res Hum Retroviruses 1993; 9 Suppl. 1: S65–9.
  Google Scholar
• World Health Organization. Scientific and public health rationale for HIV vaccine efficacy trials. AIDS 1995; 9: WH01–4
  Google Scholar
• Cohen J. US Panel votes to delay real-world vaccine trials. Science 1994; 264: 1839.
  PubMed CAS Google Scholar
• Kunasol P. International HIV/AIDS vaccine trials: expectations of host countries. AIDS Res Hum Retroviruses 1993; 9 Suppl. 1: S135–6.
  Google Scholar
• Katongole-Mbidde E. Expectations of host countries in HIV vaccine trials. AIDS Res Hum Retroviruses 9 Suppl. 1: S17–8
• Esparza J. Development of WHO-sponsored sites for HIV vaccine evaluation. AIDS Res Hum retroviruses 1993; 8 Suppl. 1: S133–4.
  Google Scholar
• Esparza J, Osmanov S, Clements ML, et al. Preparation for efficacy trials of preventive HIV candidate vaccines: the role of the World Health Organization. In: Girard M, Valette L, editors. Retroviruses of human AIDS and related animal diseases. 7e Colloque des ‘Cent Gardes’; 1992 Oct 26–28: Marnes-La-Coquette. Paris: Fondation Marcel Merieux, 1993: 217–22.
  Google Scholar
• Heyward WL, Osmanov S, Saba J, et al. Preparation for phase III HIV vaccine efficacy trials: methods for the determination of HIV incidence. AIDS 1994; 8: 1285–91.
  PubMed CAS Google Scholar
• Temoshok LR. Behavioral research contributions to planning and conducting HIV vaccine efficacy trials. AIDS Res Hum Retroviruses 1994; 10 Suppl. 2: S277–80.
  PubMed Google Scholar
• Esparza J, Osmanov S, Heyward W, et al. Ethical aspects of trials of candidate vaccines against the human immunodeficiency virus (HIV). Fourth International Seminar on Immunizations in Africa; 1994 March 13–16; Yamoussoukro, Côte d’Ivoire. Paris: Collection Fondation Marcel Merieux, 1994: 330–1
  Google Scholar
• Lurie P, Bishaw M, Chesney MA, et al. Ethical, behavioural, and social aspects of HIV vaccine trials in developing countries. JAMA 1994; 271: 295–301.
  PubMed CAS Google Scholar